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Abstract
Background: In endemic areas, Rift Valley fever virus (RVFV) is a significant threat to both human and animal health. Goals of
this study were to measure human anti-RVFV seroprevalence in a high-risk area following the 2006–2007 Kenyan Rift Valley
Fever (RVF) epidemic, to identify risk factors for interval seroconversion, and to monitor individuals previously exposed to
RVFV in order to document the persistence of their anti-RVFV antibodies.
Methodology/Findings: We conducted a village cohort study in Ijara District, Northeastern Province, Kenya. One hundred
two individuals tested for RVFV exposure before the 2006–2007 RVF outbreak were restudied to determine interval anti-
RVFV seroconversion and persistence of humoral immunity since 2006. Ninety-two additional subjects were enrolled from
randomly selected households to help identify risk factors for current seropositivity. Overall, 44/194 or 23% (CI95%:17%–29%)
of local residents were RVFV seropositive. 1/85 at-risk individuals restudied in the follow-up cohort had seroconverted since
early 2006. 27/92 (29%, CI95%: 20%–39%) of newly tested individuals were seropositive. All 13 individuals with positive titers
(by plaque reduction neutralization testing (PRNT80)) in 2006 remained positive in 2009. After adjustment in multivariable
logistic models, age, village, and drinking raw milk were significantly associated with RVFV seropositivity. Visual impairment
(defined as #20/80) was much more likely in the RVFV-seropositive group (P,0.0001).
Conclusions: Our results highlight significant variability in RVFV exposure in two neighboring villages having very similar
climate, terrain, and insect density. Among those with previous exposure, RVFV titers remained at .1:40 for more than 3
years. In concordance with previous studies, residents of the more rural village were more likely to be seropositive and RVFV
seropositivity was associated with poor visual acuity. Raw milk consumption was strongly associated with RVFV exposure,
which may represent an important new focus for public health education during future RVF outbreaks.
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Introduction
Rift Valley Fever (RVF) is a life-threatening, mosquito-borne
zoonotic disease found in many areas of sub-Saharan Africa and the
Middle East [1]. Because Rift Valley fever virus (RVFV) readily
infects both humans and their livestock, RVF poses a severe, dual
threat to public health and to livestock food production in endemic
regions [2,3]. Of particular concern, the range of RVFV
transmission has extended beyond sub-Saharan Africa over the last
35 years [4–6]. Future RVFV spread beyond its present enzootic
areas, whether through natural livestock/vector movement or
through bioterrorist action, poses a significant threat to many
countries. RVFV, a member of the genus Phlebovirus, is a mosquito-
borne virus that is maintained within ecosystems by vertical
transmission among local floodwater Aedes spp. mosquitoes [7].
Typically, in enzootic regions, these transient vectors reintroduce
RVFV into local mammalian fauna following periods of heavy
rainfall, after which other hematophagous vectors, typically culicine
mosquitoes, serve to perpetuate transmission [8]. In addition,
transmission of RVFV can also occur via aerosol or direct contact
with infected animals or their body fluids [9].
RVFV infection causes serious disease in both human and
animal populations, resulting in significant agricultural, economic
and public health consequences. Although in the majority of
human cases RVFV causes a mild, acute febrile illness with fever,
malaise, and myalgia, a minority of human cases are complicated
by retinitis (10%), encephalitis (8%), and hemorrhagic fever (1%)
with significant risk of related morbidity and mortality [9–18].
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frequently causes hemorrhagic disease and ‘‘abortion storms’’ that
are associated with high mortality among domestic sheep, goats,
and cattle [3,19,20].
In 2006–2007, a major Rift Valley Fever outbreak resulted in
significant human and animal disease across East Africa, including
parts of Kenya, Tanzania, Sudan, and Somalia [21,22]. In Kenya,
684 human cases were reported of whom 333 were from
Northeastern Province, the focus of our present study [21].
Having conducted a serosurvey in Ijara District in 2006, just prior
to the 2006–2007 outbreak, we then performed a follow-up survey
in 2009 in order to: (i) quantify the new local level of anti-RVFV
seroprevalence in the human population; (ii) identify risk for
seroconversion; and (iii) monitor previously exposed individuals to
estimate the persistence of their post-infection immune response.
Methods
Ethics Statement
All adult participants provided written informed consent under
a protocol approved by the Human Investigations Review Board
of University Hospitals of Cleveland and by the Ethical Review
Committee of the Kenya Medical Research Institute, Nairobi.
Parents provided written informed consent for participating
children; children .7 years of age also provided individual assent.
Location
Our study was a household-based cluster sampling of human
populations residing in 2 areas near Masalani Town, Ijara District,
situated in a semiarid region of Northeastern Province, Kenya
(Figure 1).
The study was performed in August through November of 2009,
,3 years after the previous RVF outbreak of 2006–2007 [22]. This
population was previously tested for RVFV in early 2006 [23] prior
to the latest major RVF outbreak, and was revisited to re-enroll
previous participants in order to monitor incidence and anti-RVFV
IgG seroprevalence changes since the last outbreak. The partici-
pants were selected from two villages: a rural village, Gumarey
(centered at 1u409120S, 40u09480E), and a town, Sogan-Godud
(centered at 1u419240S, 40u109120E). Both are sublocations of the
Masalani Division of Ijara District as defined within the Kenya
Census, and both have suffered repeated RVF outbreaks, most
recently in 1997–1998 [24] and 2006–2007 [22]. Gumarey is more
rural having a predominantly semi-nomadic pastoralist population.
Sogan-Godud is a larger town with a central marketplace with a
more permanent population (Figure 1).
Objectives
Participants were either newly enrolled or re-enrolled for anti-
RVFV IgG testing following a RVF epidemic/epizootic in
Masalani Town, Northeastern Province. Sera were tested for the
presence of anti-RVFV IgG antibodies by standardized testing
(indicative of previous exposure to virus infection). The follow-up
specimens were obtained to identify seroconversions following a
known RVF outbreak and to investigate epidemiologic risk factors
that were related to current seropositivity. For those who had been
seropositive in 2006, we also wished to estimate the temporal
duration of RVF antibody positivity. Given the extensive nature of
the 2006–2007 RVF outbreak in this region and the longstanding
history of RVF in Kenya, we hypothesized that we would be able
to identify .13% of individuals in these villages as seropositive for
anti-RVFV antibodies, and that our follow-up cohort would
contain seroconverters after the outbreak. We conducted an
extensive behavioral survey to elicit a greater understanding of
risk-related RVFV exposure factors and to identify risk behaviors
that might be relevant for targeted public health activities.
Participants
Study recruitment began after consultation and approval by
local leaders and administrators. After an initial demographic
census was performed to determine the current local population
and its distribution, up to three attempts were made to contact and
re-enroll each participant from our previous serosurvey [23].
Another group of new survey participants were randomly selected
by household clusters in the 2 designated villages of Masalani
town. Those living in the area less than 2 years and children more
than 1 year of age were excluded. The study sample was
representative of the local ethnic mix of .99% Somali or Bantu
and ,1% Indian or other Asian. Participating households were
sampled by using a probability of selection proportionate to size
approach. Households were randomly selected until we reached
our sample size goal of 200 enrolled individuals.
Examination Procedures
Study participants each received a formal interview detailing
demographics, occupation, housing, mosquito exposure, animal
exposure, motor ability, visual ability, and recent or remote RVF-
related symptoms (questionnaire in Appendix S1). When neces-
sary, accompanying parents served as proxies in answering for
younger children. Each subject also received a complete physical
examination, vision testing, and indirect ophthalmoscopic exam-
ination for signs of current or previous retinal inflammation.
Serology testing was performed on specimens obtained by same-
day phlebotomy (i.e., venous blood samples 5 ml in those $5 years
of age and 1 ml in children ,5 years of age).
Laboratory Testing
RVFV exposure was initially determined by serum anti-RVFV IgG
detection using ELISA [23,25,26] and confirmed by plaque reduction
neutralization testing (PRNT80) [27,28]. A PRNT80 titer of .1:20 was
Author Summary
RVFV infection causes significant disease in both human
and animal populations, resulting in significant agricultur-
al, economic and public health consequences. We
conducted a cohort study on residents of a high-risk area
to measure human anti-RVFV seroprevalence, to identify
risk factors, and to estimate the durability of prior RVFV
immunity. One hundred two individuals tested for RVFV
exposure before the 2006–2007 RVF outbreak were
restudied to determine interval anti-RVFV seroconversion
and persistence of humoral immunity since 2006. Ninety-
two additional subjects were enrolled from randomly
selected households to help identify risk factors for current
seropositivity. Seroprevalence in the region was high
(23%). 1/85 at-risk individuals restudied in the follow-up
cohort had seroconverted since early 2006. 29% of newly
tested individuals were seropositive. After adjustment in
multivariable logistic models, age, village, and drinking raw
milk were significantly associated with RVFV seropositivity.
Visual impairment (defined as #20/80) was much more
likely in the RVFV-seropositive group. Among those with
previous exposure, RVFV titers remained at protective
levels (.1:40) for more than 3 years. This study highlights
the high seroprevalence among Northeastern Kenyans and
the ongoing surge in seroprevalence with each RVF
outbreak.
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were considered positive. Briefly, specimens were initially screened for
the presence of anti-RVFV IgG by ELISA by using lysates of Vero
cells infected with the MP-12 strain (vaccine strain [27]) of RVFV as
the test antigen and lysates of mock-infected cells as the internal
control antigen, as established and validated in previous survey studies
[23,25,26]. Confirmatory plaque reduction neutralization testing
(PRNT80) was performed at University of Texas, Medical Branch at
Galveston to assess the risk of false-positive results secondary to ELISA
cross-reaction with related viruses. This confirmatory testing using
PRNT80 was performed on all positive samples (n=44) and a set of
borderline negative samples (n=25) [27]. ELISA testing revealed
incongruent results with PRNT80. Five ELISA-positive samples were
negative by PRNT80 (titers,1:20). Ten ELISA-negative samples had
titers $1:20. Most ELISA positive samples had PRNT80 titers of
1:320. Overall, ELISA had 77% sensitivity, 97% specificity, 87%
positive predictive value, and 94% negative predictive value when
compared to gold standard PRNT80. All anti-RVFV serology results
discussed in this manuscript are based on PRNT80 results.
Statistical Methods
Summary statistics were computed to describe demographic
variables. The primary outcome was RVFV seropositivity as
determined by PRNT80. Bivariate analysis was based on x2 tests
(or Yates’ correction to the x2 where appropriate) of potential
categorical predictors of seropositivity as well as bivariate
comparisons between villages. Independent t-tests were used for
bivariate comparisons of continuous predictors. The multivariable
logistic regression models used for estimation of the adjusted odds
ratios for seropositivity utilized data from all 194 participants.
These models were initially developed using predictor variables
that had been determined in bivariate analysis to be significantly
associated with RVFV seropositivity. In addition, separate models
were constructed using only those subjects who were repeat survey
participants (N=102) or using only those who were new
participants (N=92). Logistic models were also constructed
separately for each village in order to determine significant local
predictors of RVFV seropositivity. A collinearity analysis was
performed examining all of the potential predictors in the models
[29]; however, no evidence of collinearity was found. Hosmer-
Lemeshow goodness-of-fit x2 square tests were calculated for all
logistic models and indicated that model predictors sufficiently
described the observed data. All bivariate analysis and logistic
modeling was performed using SAS software (SAS Institute Inc.,
version 9.2, Cary, NC, USA). A significance level of 0.05 was used
for all statistical tests.
Figure 1. Pictures of Masalani. Left upper, Gumarey homestead; Left lower, local herd; Right upper, Sogan-Godud homestead; Right lower, view
of Masalani town and Tana River from Masalani bridge.
doi:10.1371/journal.pntd.0001265.g001
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Survey results: seroprevalence by group and
seroconversion
A total of 194 participants were enrolled in this study: 102 had
participated in the previous serosurvey [23] and 92 were new
participants (Table 1). Of the total 194 participants, 44 were
RVFV seropositive (23%, CI95%: 17%–29%). Among all partic-
ipants, 81 (42%) were from the more rural village, Gumarey (GM,
from 45 households) and of these, 27 (33%, CI95%: 23%–44%)
were seropositive (See Figure 2). The remaining 113 subjects
(58%) were from the more developed area, Sogan-Godud (SG,
from 64 households) and of these, 17 (15%, CI95%: 9%–23%) were
seropositive. Of all samples, 44 (23%) were from children #15
years of age, of whom 3 (7%, CI95%: 0%–14%) were seropositive.
These 3 youngest seropositive participants were 7, 7, and 15 years
of age, and all were long-time, permanent residents of the study
area. Of the 150 adults sampled, 41 (27%, CI95%: 20%–34%) had
positive anti-RVFV IgG results; the oldest was 82 years of age.
One 77 y/o female from SG seroconverted in the interval
between testing in early 2006 and August 2009 [23]. Twenty-six
newly tested individuals were seropositive (28%, CI95%: 20%–
39%). Participants from Gumarey were more likely to be RVFV
seropositive in nearly every age group (see Figure 3).
New participants were more likely to be RVFV seropositive
(P,0.001) and have impaired visual acuity (worse than 20/40)
during eye examination (P=0.009) (Table 2). Comparison of the
new and repeat study participants demonstrated that new
participants were more likely to be older, nomadic, live in semi-
permanent housing, have recent home flooding, use mosquito
nets, use fire as mosquito control, have ill family members, have
dead body contact, have dirt flooring and have sheep and camel
contact. New participants were also more likely to report recent
symptoms of illness. New participants were less likely to report
specific animal exposures when compared to repeat participants.
Figure 2. Flow chart of study samples.
doi:10.1371/journal.pntd.0001265.g002
Table 1. Study demography and anti-Rift Valley fever virus
serology results by sex, age group, and village.
Repeat
Subjects
(N=102)
New
Subjects
(N=92)
All
Subjects
(N=194)
Sex
Female 66 (65%) 57 (62%) 123 (63%)
Male 36 (35%) 35 (38%) 71 (37%)
Age
Adults 67 (66%) 83 (90%) 150 (77%)
Children (#15 years) 35 (34%) 9 (10%) 44 (23%)
Village
Sogan-Godud 60 (59%) 53 (58%) 113 (58%)
Gumarey 42 (41%) 39 (42%) 81 (42%)
RVFV Seropositives
Both Villages 17 (17%) 27 (29%) 43 (22%)
Sogan-Godud 6 (7%) 11 (12%) 16 (8%)
Gumarey 11 (12%) 16 (17%) 27 (14%)
doi:10.1371/journal.pntd.0001265.t001
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Thirteen individuals who were confirmed anti-RVFV positive
by PRNT80 in the prior 2006 survey [23] had repeat PRNT80
performed in the current study (see Figure 4). All had positive titers
$1: 320 in 2009. Seven subjects had titers that remained
unchanged. Five had a 1- to 4-fold drop in titer. One individual
had a two-fold boost in titer from 1:320 to 1:1280.
Links between past exposures and seropositivity
Many exposures, both non-animal and animal, were associated
with RVFV seropositivity (Table 3). In bivariate statistical
analyses, RVFV seropositivity varied significantly according to
the following factors: age (participants .15 years of age were more
at risk, OR 0.20, CI95%: 0.06–0.66, P,0.001), gender (male
participants were more at risk, OR 2.33, CI95%: 1.18–4.61,
P=0.020), location (those from Gumarey were more at risk, OR
2.82, CI95%: 1.41–5.64, P=0.003), drinking raw milk (OR 2.71,
CI95%: 1.36–5.42, P=0.005), and involvement in skinning
livestock (OR 2.12, CI95%: 1.06–4.24, P=0.043), birthing
livestock (OR 3.62, CI95%:1.61–8.15, P=0.002), or disposing of
an aborted animal fetus (OR 3.49, CI95%:1.52–7.99, P=0.004).
Other reported exposures varied significantly between the 2
sublocation groups. Those from Gumarey were more likely to
shelter livestock (OR 2.2, CI95%: 1.18–3.8, P=0.013), kill livestock
(OR 2.1, CI95%: 1.03–4.16, P=0.049), or have an ill family
member (1–2 years ago OR 4.0, CI95%: 0.32, 49.60; 1–3 months
ago OR 1.04, CI95%: 0.44, 2.42; 4–6 months OR 5.33, CI95%:
1.60, 17.83; 7–12 months ago OR 10.00, CI95%: 1.03, 97.49; and
less than 1month ago OR 2.00, CI95%: 0.41, 9.71, as compared
to never having an ill family member P=0.003) (Table 4).
The final logistic model to predict RVFV seropositivity included
age, location, and drinking raw animal milk (Table 5). In
multivariable models used to predict adjusted odds of RVFV
seropositivity, location was significant when age and raw milk
consumption were controlled for; those residing in GM were at 3
times the risk of those in SG (adjusted OR 3.33; CI95%: 1.53–7.21).
After age and location were controlled for, those who had
consumed raw milk were 3 times more likely to be seropositive
(adjusted OR 2.9, CI95%: 1.34–6.27). Children #15 years of age
had a much lower risk for RVFV seropositivity than those .15
years of age. The adjusted OR for seropositivity (calculated from
the overall logistic model) was 1.04; (CI95%: 1.02–1.06) per year of
age. This difference persisted at both sublocation levels with adults
in SG or GM at significantly higher risk than children.
Models between old and new survey participants differed (Table
S1A and B). Whereas, after multivariable adjustment, older age and
male gender had the most significant association with anti-RVFV
seropositivity among repeat participants, a history of attending to a
birthing animal was the most significant predictor for new participants.
Subgroup analysis by village showed the significant predictor of
RVFV seropositivity in Sogan-Godud to be age, cooking meat,
and drinking raw milk (Table S2A). Older participants had a 4.5%
increase in odds for each year of age. Those who cooked meat
were less likely to be seropositive (adjusted OR, 0.184,
CI95%:0.042–0.81). Those who consumed raw milk were nearly
16 times more likely to be seropositive (adjusted OR 15.7, CI95%:
2.9–84.9). In Gumarey, the higher risk village, the logistic model to
predict seropositivity included age, such that the odds of
seropositivity increased 5% for every 1-year increase in age
(adjusted OR 1.05, CI95%: 1.02–1.07)(Table S2B).
Links between seropositivity and symptom history or
abnormal physical findings
A past history of malaise (OR 2.5, CI95%: 1.5–5.7, P=0.004),
backache (OR 2.6, CI95%: 1.2–5.5, P=0.014),rash (OR 3.9, CI95%:
1.5–10.0, P=0.009), stupor (OR 3.4, CI95%: 1.4–8.1, P=0.006),
confusion (OR 4.3, CI95%: 1.3–13.4, P=0.015), or bloody stools
(OR 5.4, CI95%: 1.4–20.1, P=0.013) was statistically associated
Figure 3. Seroprevalence of age groups from study villages and total sample.
doi:10.1371/journal.pntd.0001265.g003
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examination, no non-ocular examination finding was specifically
associated with RVFV seropositivity.
Regarding ocular findings, anterior and posterior chamber
abnormalities were associated with RVFV seropositivity: those with
abnormal eye exam (OR=6.2, CI95%: 1.9–20.2, P=0.002), poor
visual acuity (defined as #20/80; OR=5.1, CI95%: 2.3–11.4,
P,0.001), anterior chamber disease (P,0.001), posterior chamber
disease (OR=3.4, CI95%: 1.5–8.2, P=0.006), and retinal disease
(3.73, CI95%: 1.13–12.31, P=0.033) were more likely to be
seropositive. The ranges of measured visual acuity [6/5 to 6/60,
equivalent to 20/17–20/200)] were similar in RVFV seropositive and
seronegative groups, but visual acuity was more likely to be worse in
the RVFV seropositive group (visual impairment defined as #20/80:
43% of seronegative vs. 80% of seropositive participants; P,0.0001).
Discussion
This is the first cohort study performed on RVFV in a high-risk
area of Kenya to document seroconversion and risk over time.
This study demonstrates the significant RVFV seroprevalence (up
to 33%) in an at-risk population in Northeastern Kenya, and
highlights the differences in exposure between similar villages. Of
the newly tested individuals who were randomly sampled, 29%
were seropositive, highlighting the high risk of exposure in this
region. Older age, rural village location, raw milk consumption,
and poor visual acuity were significantly associated with RVFV
seropositivity. We also documented the maintenance of PRNT80
titers at levels that are considered to be protective from disease
over time in repeat participants.
RVFV seropositivity was relatively high in our sample
population in Masalani town, Kenya, particularly in the rural
village area (Gumarey), where seropositivity rates were twice as
high as in the town area (Sogan-Godud) regardless of only 500 m
of separation between the village sites. Our previous study also
showed that those in Gumarey were at higher risk of seropositivity
(20% vs. 6% in SG). Although seroprevalence in both villages has
increased since 2006 (currently 33% vs. 15%), the differential
between the two villages remains. Clues to the reasons for this
discrepancy in seroprevalence were identified in our study. Those
Table 2. Comparison of new and repeat participants.
New Participants Repeat Participants P value*
(N=92) (N=102)
RVFV seropositive 28% 18% ,0.0001
Poor visual acuity during eye exam 62% 43% 0.009
Age, y: Mean + SD 44.9621.0 33.2622.6 0.0003
Nomadic 89% 25% ,0.001
Live in semi-permanent housing 70% 21% ,0.001
Have recent home flooding 7% 31%, ,0.001
Use mosquito nets 93% 95%, ,0.001
Use fire as mosquito control 97% 88% ,0.001
Have ill family members 73% 94% ,0.001
Have dead body contact 14% 43% ,0.001
Have dirt flooring 88% 57% ,0.001
Animal Exposures
Sheep contact 61% 71% ,0.001
Camel contact 29% 9% ,0.001
Sheltering livestock 21% 61% ,0.001
Killing livestock 11% 30% ,0.001
Butchering livestock 20% 68% ,0.001
Milking livestock 32% 71% ,0.001
Reported recent symptoms of illness
Myalgia 52% 28% ,0.001
Eye pain 69% 20% ,0.001
Headache 86% 53% ,0.001
Red eyes 78% 33% ,0.001
No appetite 72% 29% ,0.001
Photophobia 60% 24% ,0.001
Vertigo 33% 16% ,0.001
Stupor 24% 4% ,0.001
Meningismus 46% 14% ,0.001
Poor vision 47% 19% ,0.001
*Calculated by chi-square testing with Yates’ correction, as appropriate.
doi:10.1371/journal.pntd.0001265.t002
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kinds of animal exposures than those from Sogan-Godud. Village-
specific models to predict seropositivity differ: age was the only
independent predictor in Gumarey, suggesting that continued
exposure over a life-time is the most important factor in this high
risk village. In comparison, the model in SG highlighted both age
and drinking raw milk, a factor that was important in the overall
model for the entire study sample. Outbreak education may need
to take village factors into account. As prediction tools are refined,
better resolution may be needed to more accurately predict risk,
since risk varies at such a small scale.
Our 2009 testing indicated that children had less evidence of
past RVFV exposure than did adults in the same study cohort.
This may be because children had less high-risk animal contact
than adults. Alternatively, because we observed such an apparently
low RVFV infection incidence among villagers in our study, it
cannot be excluded that the study villages were not as heavily
exposed to RVFV during the 2006–2007 outbreak as they had
been in 1997–1998 RVFV outbreak. Because most children
sampled in the present 2009 survey were born after the 1997–98
outbreak, if 2006–2007 transmission had been relatively low, their
2009 serostatus would be much more likely to remain negative in
2009.
PRNT80 titers remained high in individuals who were positive
in the previous serosurvey, supporting previous expert opinion that
development of anti-RVFV neutralizing titers through natural
infection is likely to confer long-term protection against reinfec-
tion. Of note, one 54 y/o businessman had a boost in titer but did
not report any signs of RVFV or animal contact in the last three
years. He may have been re-exposed to RVFV, but suffered no
clinical disease because of adaptive immunity persisting from a
prior exposure.
In contrast to our previous studies, ELISA testing was not fully
congruent with PRNT80. Ongoing repeat testing by PRNT80 will
illustrate whether cross reactivity represented exposure to a
concomitant circulating Bunyavirus.
Consumption of raw animal milk was associated with nearly 3
times the odds of RVFV seropositivity. Epidemiologic studies
during RVF outbreaks have shown that drinking raw milk
increases human risk for RVF disease, although whether the
route of transmission is the direct consumption of infective raw
milk or secondary to an alternate behavioral risk has not been
determined [23,24,30,31]. Analysis of milk products from
experimentally infected animals provides conflicting evidence of
virus infectivity in this body fluid [32–35] and attempts to infect
offspring via suckling have failed to demonstrate transmission [2].
It is possible that the association that we detected between raw
milk consumption and RVFV seropositivity is not causal and may
represent some unmeasured variable, although history of milking
livestock was not associated with RVFV seropositivity. Laboratory
based experiments to determine the viability and transmissibility of
RVFV in milk are warranted.
The most common sequela of RVFV infection is uveitis. Persons
who were RVFV seropositive were more likely to have poor visual
acuity, but a large portion of the study sample had poor eyesight.
RVFV is one of many eye diseases present in Kenya. It is likely
that RVFV along with trachoma, West Nile virus, chikungunya
virus, dengue virus, and others all contribute to the significant
burden of poor vision in our cohort.
Apart from eye disease, no physical examination finding was
associated with RVFV seropositivity, although several RVFV-
associated symptoms were reported among those who were RVFV
seropositive. Many were severe manifestations of RVF disease,
such as bloody stools, confusion, and stupor. Confusion and stupor
may represent those with history of RVF encephalitis. Malaise,
backache, and rash may represent those with history of mild RVF
or other illnesses.
Our study was limited by its small sample size; although three
attempts were made to re-enroll our 248 previous participants,
only 102 were studied. Because only one individual seroconverted
we cannot draw conclusions about whether the identified risk
factors specifically caused RVFV exposure. Reported associated
symptoms may have been due to other infections; for example,
RVF is usually not associated with rash. Our study had a larger
proportion of women, since the men in this community are often
herding and may not be near the homestead. This bias in our
Figure 4. Plaque Reduction Neutralization Titer (PRNT80) of 13 individuals with repeated testing.
doi:10.1371/journal.pntd.0001265.g004
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RVFV exposure in this community, since males are more at risk.
The validity of the associations in this study relies on accurate
recall of exposures by the study participants and our study may
have limited generalizability.
This study highlights the high seroprevalence among North-
eastern Kenyans and the ongoing surge in seroprevalence with
each RVF outbreak. Consumption of raw milk may be an easy
target for effective prevention of RVF during outbreaks and
warrants further study. Local public health agencies may need to
target specific protective interventions according to risk factors in
different populations.
Table 3. Bivariate analysis of anti-RVFV seropositivity
according to demographic and exposure factors.
Variable* P value{
Odds ratio
(95% Confidence
Interval)
Age (continuous) ,0.001 1.04 (1.02, 1.06)
Location (Gumarey vs. Sogan-Godud) 0.003 2.82 (1.41, 5.64)
Gender (Male vs. female) 0.020 2.33 (1.18, 4.61)
Shelter cow 0.006 3.81 (1.54, 9.38)
Kill cow 0.002 6.40 (1.98, 20.73)
Skin animal 0.043 2.12 (1.06, 4.24)
Skin cow 0.038 2.42 (1.07, 5.46)
Drank raw milk 0.005 2.71 (1.36, 5.42)
Drank raw sheep milk 0.035 2.11 (1.07, 4.16)
Drank raw cow milk 0.043 2.12 (1.06, 4.24)
Assist with birthing livestock 0.002 3.62 (1.61, 8.15)
Assist with birthing sheep 0.007 3.35 (1.43, 7.85)
Assist with birthing goat 0.007 3.35 (1.43, 7.85)
Assist with birthing cow ,0.001 8.47 (2.72, 26.40)
Dispose of aborted animal fetus 0.004 3.49 (1.52, 7.99)
Dispose of aborted sheep fetus 0.005 3.62 (1.53, 8.56)
Dispose of aborted goat fetus 0.021 2.98 (1.25, 7.08)
Dispose of aborted cow fetus 0.007 4.51 (1.53, 13.25)
Recent malaise 0.039 2.47 (1.07, 5.73)
Recent backache 0.014 2.57 (1.20, 5.48)
Recent rash 0.009 3.85 (1.48, 10.00)
Recent confusion 0.015 4.26 (1.35, 13.44)
Recent stupor 0.006 3.40 (1.44, 8.06)
Recent bloody stool 0.013 5.41 (1.45, 20.15)
Anterior chamber disease ,0.001 N/A
Posterior chamber disease 0.006 3.45 (1.46, 8.15)
Retinal disease 0.033 3.73 (1.13, 12.31)
Abnormal eye exam 0.003 6.21 (1.91, 20.20)
Poor visual acuity (#20/80) ,0.001 5.09 (2.28, 11.32)
*All variables were dichotomous except age (continuous).
{Pearson x
2 test with Yates’ continuity correction was used for all variables
except age (continuous), which used independent samples 2-tailed t test.
doi:10.1371/journal.pntd.0001265.t003
Table 4. Bivariate analysis of demographic and other
exposure factors for anti-RVFV seropositivity by village
location.
Variable P value{
Odds ratio comparing
Gumarey vs. Sogan-
Godud
(95% C.I.)
When ill family member (ordinal) 0.003
1–2 yrs 4.00 (0.32, 49.60)
1–3 months 1.04 (0.44, 2.42)
4–6 months 5.33 (1.60, 17.83)
7–12 months 10.00 (1.03, 97.49)
Less than 1 month 2.00 (0.41, 9.71)
Never (reference) 1.00
Latrine type 0.045
VIP 0.60 (0.06, 6.08)
Bush 2.23 (1.12, 4.46)
Pit 0.90 (0.43, 1.90)
Toilet (reference) 1.00
Shelter livestock in home 0.013 2.19 (1.18, 3.80)
Shelter sheep in home 0.012 2.16 (1.20, 3.90)
Shelter goat in home 0.007 2.35 (1.30, 4.26)
Shelter cow in home ,0.001 6.11 (2.16, 17.27)
Kill livestock 0.049 2.07 (1.03, 4.16)
Kill sheep 0.047 2.08 (1.02, 4.24)
Kill goat 0.019 2.38 (1.16, 4.87)
Kill cow 0.017 5.12 (1.36, 19.24)
Assist with sheep birth 0.021 2.71 (1.17, 6.28)
Assist with goat birth 0.006 3.27 (1.39, 7.72)
Assist with cow birth 0.002 6.32 (1.72, 23.20)
Dispose of sheep fetus 0.011 3.04 (1.28, 7.23)
Dispose of goat fetus 0.011 3.04 (1.28, 7.23)
Dispose of cow fetus 0.014 4.24 (1.30, 13.84)
Herder occupation 0.058 2.97 (0.97, 9.07)
Recent fever 0.034 1.96 (1.06, 3.63)
doi:10.1371/journal.pntd.0001265.t004
Table 5. Logistic Regression Analysis to predict Rift Valley fever virus seropositivity.
Predictor variable Variable type Adjusted OR (CI) P value
Age Continuous 1.04 (1.02–1.06) ,0.0001
Location (Gumarey vs. Sogan-Godud) Dichotomous 3.3 (1.5–7.2) 0.003
Drank raw milk Dichotomous 2.9 (1.3–6.3) 0.006
Logistic Model 1, all participants*.
*CI, 95% confidence interval. Goodness-of-fit: Hosmer and Lemeshow test, p value=0.489; R
2=28.6%.
doi:10.1371/journal.pntd.0001265.t005
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